Elanco Animal Health (NYSE:ELAN) Posts Earnings Results, Beats Expectations By $0.06 EPS

Key Points

• Elanco Animal Health reported earnings of $0.26 per share for the quarter, exceeding analysts' expectations of $0.20, and achieved revenues of $1.24 billion, also surpassing the predicted $1.19 billion.
• The company has updated its Q3 2025 guidance to a projected EPS range of 0.120-0.160 and FY 2025 guidance to 0.850-0.91 EPS.
• Elanco's stock saw a recent upward adjustment in ratings from several research firms, with most analysts now giving it a consensus rating of "Moderate Buy" and an average price target of $16.17.

Elanco Animal Health (NYSE:ELAN - Get Free Report) posted its earnings results on Thursday. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.06, Zacks reports. The firm had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%. The firm's revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.30 earnings per share. Elanco Animal Health updated its Q3 2025 guidance to 0.120-0.160 EPS and its FY 2025 guidance to 0.850-0.91 EPS.

Elanco Animal Health Stock Up 1.9%

Shares of ELAN traded up $0.33 during mid-day trading on Tuesday, reaching $17.43. 2,784,139 shares of the stock traded hands, compared to its average volume of 5,428,253. The firm has a market cap of $8.66 billion, a price-to-earnings ratio of 20.30, a P/E/G ratio of 3.12 and a beta of 1.66. The stock has a fifty day simple moving average of $14.39 and a 200 day simple moving average of $12.12. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $17.48. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61.

Analyst Ratings Changes

ELAN has been the subject of a number of research reports. Stifel Nicolaus raised their price objective on Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Leerink Partnrs raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target on the stock in a research note on Thursday, July 17th. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Finally, UBS Group increased their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.33.

Institutional Investors Weigh In On Elanco Animal Health

Large investors have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Elanco Animal Health by 4.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company's stock worth $18,830,000 after acquiring an additional 76,408 shares during the period. Empowered Funds LLC grew its position in shares of Elanco Animal Health by 35.2% in the first quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock valued at $166,000 after purchasing an additional 4,121 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock valued at $50,268,000 after buying an additional 2,445,872 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Elanco Animal Health during the first quarter worth about $2,065,000. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.